Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission (Q24235952)

title

Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission (English)

0 references

1 reference

lymphoblastic leukemia

1 reference

2

0 references

author name string

Joseph Pidala

1

0 references

Claudio Anasetti

3

0 references

Mohamed Kharfan-Dabaja

4

0 references

Ambuj Kumar

5

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21975786

full work available at URL

13 December 2024

publication date

5 October 2011

0 references

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386902

file format

HyperText Markup Language

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975786

https://europepmc.org/articles/PMC7386902

13 December 2024

file format

HyperText Markup Language

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975786

https://europepmc.org/articles/PMC7386902?pdf=render

13 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975786

https://doi.org/10.1002/14651858.cd008818.pub2

13 December 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21975786

https://onlinelibrary.wiley.com/doi/full/10.1002/14651858.CD008818.pub2

13 December 2024

1 reference

10.1002/14651858.CD008818.PUB2

DOI

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Cochrane Database of Systematic Reviews

13 December 2024

published in

0 references

cites work

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

A review of blinding in randomized controlled trials found results inconsistent and questionable

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Comparison of two methods to detect publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Unequal group sizes in randomised trials: guarding against guessing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Treatment of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD008818.PUB2

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

21 January 2018

1 reference

12 December 2020

Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups

1 reference

12 December 2020

Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group

1 reference

12 December 2020

Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transp

1 reference

12 December 2020

Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia

1 reference

12 December 2020

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

1 reference

12 December 2020

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

1 reference

12 December 2020

Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial

1 reference

12 December 2020

Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia

1 reference

12 December 2020

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

12 December 2020

Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission

1 reference

12 December 2020

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study

1 reference

12 December 2020

Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial

1 reference

12 December 2020

10.1002/14651858.CD008818.PUB2

Identifiers

DOI

0 references

PMC publication ID

7386902

0 references